Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 36, Issue 4

Issues

A Time-Resolved Fluorescence Immunoassay for the Measurement of Testosterone in Saliva: Monitoring of Testosterone Replacement Therapy with Testosterone Buciclate

Matthias Tschöp / Hermann M. Behre / Eberhard Nieschlag / Regina A. Dressendörfer / Christian J. Strasburger
Published Online: 2005-06-01 | DOI: https://doi.org/10.1515/CCLM.1998.038

Abstract

Monitoring of testosterone replacement therapy requires a reliable method for testosterone measurement. Determination of salivary testosterone, which reflects the hormone's biologically active plasma fraction, is a superior technique for this purpose. The aim of the present study was to establish a new sensitive time-resolved fluorescence immunoassay for the accurate measurement of testosterone levels in saliva and to validate it by monitoring testosterone replacement therapy in eight hypogonadal men.

A clinical phase I-study with the new ester testosterone buciclate was performed to search for new testosterone preparations to produce constant serum levels in the therapy of male hypogonadism. After two control examinations eight male patients with primary hypogonadism were randomly assigned to two treatment groups (n= 2×4) and given single doses of either 200 mg (group I) or 600 mg (group II) testosterone buciclate intramuscularly. Saliva and blood samples were obtained 1, 2, 3, 5 and 7 days post injection and then weekly for three months.

The time-resolved fluorescence immunoassay for salivary testosterone shows a detection limit of 16 pmol/l, an intra-assay CV of 8.9 % (at a testosterone concentration of 302 pmol/l), an inter-assay CV of 8.7 % (at a testosterone concentration of 305 pmol/l) and a good correlation with an established radioimmunsassay of r=0.89. The sample volume required by this method is only 180 μl for extraction and duplicate determination. The assay procedure requires no more than three hours.

In group I (200 mg) testosterone did not increase to normal levels either in saliva or in serum. However, in group II, androgen levels increased significantly and were maintained in the normal range for up to 12 weeks with maximal salivary testosterone levels of 303 ±18 pmol/l (mean ±SE) and maximal testosterone levels of 13.1 ±0.9 nmol/l (mean±SE) in serum in study week 6 and 7.

The time-resolved fluorescence immunoassay for salivary testosterone provides a useful tool for monitoring androgen status in men and women and is well suited for the follow-up of testosterone replacement therapy on an outpatient basis. The long-acting ester testosterone buciclate is a promising agent for substitution therapy of male hypogonadism and in combination with testosterone monitoring in saliva offers an interesting new perspective for male contraception.

About the article

Published Online: 2005-06-01

Published in Print: 1998-04-30


Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 36, Issue 4, Pages 223–230, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.1998.038.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
George G. Klee and Donald W. Heser
Mayo Clinic Proceedings, 2000, Volume 75, Number 1, Page S19
[2]
José A. Murillo Pulgarín, Aurelia Alañón Molina, and Ignacio Sánchez-Ferrer Robles
Applied Spectroscopy, 2010, Volume 64, Number 8, Page 949
[3]
Nikolai Goncharov, Gulinara Katsya, Anna Dobracheva, Alexander Nizhnik, Galina Kolesnikova, Victor Herbst, and Jürgen Westermann
The Aging Male, 2006, Volume 9, Number 2, Page 111
[4]
Franco Mazzei, Riccarda Antiochia, Francesco Botrè, Gabriele Favero, and Cristina Tortolini
Bioanalysis, 2014, Volume 6, Number 2, Page 225
[5]
Johan K.M. Aps and Luc C. Martens
Forensic Science International, 2005, Volume 150, Number 2-3, Page 119
[6]
John S. Mitchell and Tim E. Lowe
Journal of Immunological Methods, 2009, Volume 349, Number 1-2, Page 61
[7]
Jean Fiet, Frank Giton, Ibrahim Fidaa, Alain Valleix, Hervé Galons, and Jean-Pierre Raynaud
Steroids, 2004, Volume 69, Number 7, Page 461
[8]
J. Manolopoulou, P. Mulatero, C. Maser-Gluth, P. Rossignol, A. Spyroglou, Y. Vakrilova, S. Petersenn, O. Zwermann, P.F. Plouin, M. Reincke, and M. Bidlingmaier
Steroids, 2009, Volume 74, Number 10-11, Page 853
[9]
Min Sun, Jenny Manolopoulou, Ariadni Spyroglou, Felix Beuschlein, Constanze Hantel, Zida Wu, Maximilian Bielohuby, Andreas Hoeflich, Chao Liu, and Martin Bidlingmaier
Steroids, 2010, Volume 75, Number 13-14, Page 1089
[10]
Min Sun and Chao Liu
Journal of Biomedical Research, 2011, Volume 25, Number 3, Page 213
[12]
Anne McKie, Andrew Vyse, and Christopher Maple
The Lancet Infectious Diseases, 2002, Volume 2, Number 1, Page 18
[14]
M. Trottmann, M. Dickmann, C.G. Stief, and A.J. Becker
Der Urologe, 2010, Volume 49, Number 1, Page 11
[15]
Katarzyna Tyszczuk
Analytical and Bioanalytical Chemistry, 2008, Volume 390, Number 7, Page 1951
[16]
Emily Darby and Bradley D Anawalt
Treatments in Endocrinology, 2005, Volume 4, Number 5, Page 293
[17]
Louis J G Gooren and Mathijs C M Bunck
Drugs, 2004, Volume 64, Number 17, Page 1861

Comments (0)

Please log in or register to comment.
Log in